| Nov 14 |
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
|
| Nov 13 |
Prime Medicine GAAP EPS of -$0.44 misses by $0.01, revenue of $0.21M misses by $5.7M
|
| Nov 12 |
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 11 |
CRISPR, Beam, other gene editing names up significantly
|
| Oct 28 |
12 High-Growth Stocks That Could Deliver Parabolic Returns
|
| Oct 24 |
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
|
| Oct 16 |
Why I Keep Buying These 14 Incredible Growth Stocks
|
| Oct 15 |
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
|
| Oct 1 |
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
|
| Oct 1 |
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
|
